Recommendation of the President – Mexiletine
On 22 November 2024, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 132/2024 on the appropriateness of issuing approvals for reimbursement of medicinal products containing mexiletine for the indications: Myotonic dystrophy type I, myotonic dystrophy type II, myotonic syndrome, Becker myotonia, Thomsen myotonia, congenital paramyotonia, hyperkalaemic periodic paralysis, paramyotonic periodic paralysis, ventricular arrhythmias, paroxysmal atrial fibrillation, recurrent electrical storms, prolonged QT syndrome